Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 172

1.

Micafungin versus amphotericin B lipid complex for the prevention of invasive fungal infections in high-risk liver transplant recipients.

Sun HY, Cacciarelli TV, Singh N.

Transplantation. 2013 Sep;96(6):573-8. doi: 10.1097/TP.0b013e31829d674f.

PMID:
23842191
2.

Outcomes associated with amphotericin B lipid complex (ABLC) prophylaxis in high-risk liver transplant patients.

Saliba F, Delvart V, Ichaï P, Kassis N, Botterel F, Mihaila L, Azoulay D, Adam R, Castaing D, Bretagne S, Samuel D.

Med Mycol. 2013 Feb;51(2):155-63. doi: 10.3109/13693786.2012.701765. Epub 2012 Jul 17.

PMID:
22800082
3.

Randomized trial of micafungin for the prevention of invasive fungal infection in high-risk liver transplant recipients.

Saliba F, Pascher A, Cointault O, Laterre PF, Cervera C, De Waele JJ, Cillo U, Langer RM, Lugano M, Göran-Ericzon B, Phillips S, Tweddle L, Karas A, Brown M, Fischer L; TENPIN (Liver Transplant European Study Into the Prevention of Fungal Infection) Investigators; TENPIN Liver Transplant European Study Into the Prevention of Fungal Infection Investigators.

Clin Infect Dis. 2015 Apr 1;60(7):997-1006. doi: 10.1093/cid/ciu1128. Epub 2014 Dec 17.

4.

Safety and Efficacy of Intermittent Intravenous Administration of High-Dose Micafungin.

Neofytos D, Huang YT, Cheng K, Cohen N, Perales MA, Barker J, Giralt S, Jakubowski A, Papanicolaou G.

Clin Infect Dis. 2015 Dec 1;61 Suppl 6:S652-61. doi: 10.1093/cid/civ818.

5.

Risk stratification and targeted antifungal prophylaxis for prevention of aspergillosis and other invasive mold infections after liver transplantation.

Hellinger WC, Bonatti H, Yao JD, Alvarez S, Brumble LM, Keating MR, Mendez JC, Kramer DJ, Dickson RC, Harnois DM, Spivey JR, Hughes CB, Nguyen JH, Steers JL.

Liver Transpl. 2005 Jun;11(6):656-62.

6.

Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study.

Mehta PA, Vinks AA, Filipovich A, Bleesing J, Jodele S, Jordan MB, Marsh R, Tarin R, Edwards S, Fearing D, Lawrence J, Davies SM.

Biol Blood Marrow Transplant. 2010 Oct;16(10):1458-62. doi: 10.1016/j.bbmt.2010.05.002. Epub 2010 Jun 20. Erratum in: Biol Blood Marrow Transplant. 2011 Mar;17(3):441.

7.

Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.

Moen MD, Lyseng-Williamson KA, Scott LJ.

Drugs. 2009;69(3):361-92. doi: 10.2165/00003495-200969030-00010. Review.

PMID:
19275278
8.

Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis.

Kubiak DW, Bryar JM, McDonnell AM, Delgado-Flores JO, Mui E, Baden LR, Marty FM.

Clin Ther. 2010 Apr;32(4):637-48. doi: 10.1016/j.clinthera.2010.04.005.

PMID:
20435233
9.

Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation.

Hiramatsu Y, Maeda Y, Fujii N, Saito T, Nawa Y, Hara M, Yano T, Asakura S, Sunami K, Tabayashi T, Miyata A, Matsuoka K, Shinagawa K, Ikeda K, Matsuo K, Tanimoto M; West-Japan Hematology and Oncology Group.

Int J Hematol. 2008 Dec;88(5):588-95. doi: 10.1007/s12185-008-0196-y. Epub 2008 Nov 29.

PMID:
19039629
10.

Multicenter, randomized, open-label study comparing the efficacy and safety of micafungin versus itraconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant.

Huang X, Chen H, Han M, Zou P, Wu D, Lai Y, Huang H, Chen X, Liu T, Zhu H, Wang J, Hu J.

Biol Blood Marrow Transplant. 2012 Oct;18(10):1509-16. doi: 10.1016/j.bbmt.2012.03.014. Epub 2012 Mar 30.

11.
12.

Comparison of posaconazole versus weekly amphotericin B lipid complex for the prevention of invasive fungal infections in hematopoietic stem-cell transplantation.

Chaftari AM, Hachem RY, Ramos E, Kassis C, Campo M, Jiang Y, Prince RA, Wang W, Raad II.

Transplantation. 2012 Aug 15;94(3):302-8. doi: 10.1097/TP.0b013e3182577485.

PMID:
22814329
13.

Efficacy and safety of micafungin for treatment of serious Candida infections in patients with or without malignant disease.

Cornely OA, Marty FM, Stucker F, Pappas PG, Ullmann AJ.

Mycoses. 2011 Nov;54(6):e838-47. doi: 10.1111/j.1439-0507.2011.02045.x. Epub 2011 Jun 13.

PMID:
21668522
14.
16.

[Is micafungin useful in the prophylaxis of invasive fungal disease in hematological patients?].

Salavert M, Jarque I.

Enferm Infecc Microbiol Clin. 2011 Mar;29 Suppl 2:43-9. doi: 10.1016/S0213-005X(11)70009-X. Review. Spanish.

PMID:
21420577
17.

Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation.

Borro JM, Solé A, de la Torre M, Pastor A, Fernandez R, Saura A, Delgado M, Monte E, Gonzalez D.

Transplant Proc. 2008 Nov;40(9):3090-3. doi: 10.1016/j.transproceed.2008.09.020.

PMID:
19010204
19.

Refractory neonatal candidemia and high-dose micafungin pharmacotherapy.

Natarajan G, Lulic-Botica M, Aranda JV.

J Perinatol. 2009 Nov;29(11):738-43. doi: 10.1038/jp.2009.75. Epub 2009 Sep 24.

PMID:
19776753
20.

Comparison of micafungin and voriconazole in the treatment of invasive fungal infections in kidney transplant recipients.

Shang W, Feng G, Sun R, Wang X, Liu W, Zhang S, Li J, Pang X, Wang Y, Zhang W.

J Clin Pharm Ther. 2012 Dec;37(6):652-6. doi: 10.1111/j.1365-2710.2012.01362.x. Epub 2012 Jun 21.

PMID:
22725946

Supplemental Content

Support Center